September 2020 - Biologics by McKesson

GAVRETO™ (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Sep 17, 2020 | Press Release

CARY, N.C., September 17, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETO™ (pralsetinib) for the treatment of adult...

GAVRETO™ (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Recent Posts

Archives